Exclusive

Publication

Byline

OMRON Healthcare Begins Full-Scale Production at First Factory in India

New Delhi, Oct. 31 -- Chennai Factory strengthens domestic blood pressure monitor supply and supports preventive cardiovascular care in India Chennai (Tamil Nadu) [India], October 31: ... Read More


PM Modi pays floral tribute to Sardar Patel on his 151st birth anniversary at Statue of Unity

New Delhi, Oct. 31 -- Prime Minister Narendra Modi paid floral tributes to the Iron Man of India, Sardar Vallabhbhai Patel, at the Statue of Unity in Ekta Nagar, Narmada district of Gujarat, on his 15... Read More


2 foreigners die in Bengaluru hotel pool 'shock'

Dhaka, Oct. 31 -- A German and a Slovak national have died after a suspected electric shock in the swimming pool of a luxury hotel in India's Bengaluru. Indian police said the incident took place on ... Read More


Samor Reality to hold board meeting

Mumbai, Oct. 31 -- Samor Reality will hold a meeting of the Board of Directors of the Company on 6 November 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More


Singapore Clinical Trial: A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo... Read More


Singapore Clinical Trial: A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3841136 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3841136 in Healthy Participants.

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailabili... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine (MK-5884) Versus Placebo for the Prevention of COPD Exacerbations in Adults with a History of Moderate or Severe Exacerbations While Receiving Standard of Care (ENHANCE-3)

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety ... Read More


Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4174794 in Participants with Obesity or Overweight who are Otherwise Healthy

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to ... Read More


Singapore Clinical Trial: A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Sever... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutamide Compared with ARPI or Docetaxel in Patients with Metastatic Castration Resistant Prostate Cancer Previously Treated with Abiraterone Acetate (Himalayas-1)

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutami... Read More